NCT04891757 - FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

June 14, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

June 30, 2027

Conditions

Advanced Hematologic MalignancyRelapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRelapsed Myelodysplastic SyndromesRefractory Myelodysplastic SyndromesRelapsed Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic Leukemia

Interventions

DRUG

FHD-286

FHD-286 administered orally

DRUG

Low Dose Cytarabine

LDAC administered subcutaneously (SC)

DRUG

Decitabine

Decitabine administered intravenously

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

37232

Vanderbilt University Medical Center, Nashville

77030

MD Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

02215

Dana Farber Cancer Institute, Boston